The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Goldina T.A.

Sanofi Russia

Zhigunova D.S.

Ligand Research LLC

Sinyagina M.A.

Ligand Research LLC

Frolova Ya.S.

Ligand Research LLC

Monitoring in non-interventional studies

Authors:

Goldina T.A., Zhigunova D.S., Sinyagina M.A., Frolova Ya.S.

More about the authors

Read: 2479 times


To cite this article:

Goldina TA, Zhigunova DS, Sinyagina MA, Frolova YaS. Monitoring in non-interventional studies. Medical Technologies. Assessment and Choice. 2020;42(4):21‑29. (In Russ.)
https://doi.org/10.17116/medtech20204204121

Recommended articles:
The algo­rithm for clinical and audiological obse­rvation of children born preterm. Russian Bulletin of Otorhinolaryngology. 2025;(1):20-28
Cough diagnosis: from origins to modern times (review of lite­rature). Journal of Respiratory Medi­cine. 2025;(1):38-42

References:

  1. Goldina TA, Suvorov NI. Real-World Data Studies: from Data to Health Technology Assessment and Decision-Making in Healthcare. Medical Technologies. Assessment and Choice. 2018;1(31):21-29. (In Russ.).
  2. Solodovnikov AG, Sorokina EYu, Goldina TA. Real-world data: from planning to analysis. Medical Technologies. Assessment and Choice. 2020;3(41):9-16. (In Russ.). https://doi.org/10.17116/medtech2020410319
  3. Belousov DYu. Non-interventional studies. Kachestvennaya klinicheskaya praktika. 2017;1:24-33. (In Russ.).
  4. Guidance for Industry. Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring. U.S. Department of Health and Human Services. Food and Drug Administration. August 2013. Accessed September 20, 2020. https://www.fda.gov/media/116754/download
  5. Reflection paper on risk based quality management in clinical trials. European Medicines Agency, 2013. Accessed September 20, 2020. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-risk-based-quality-management-clinical-trials_en.pdf
  6. Code of Federal Regulations — Title 21 — Food and Drugs. Accessed September 20, 2020. https://www.fda.gov/medical-devices/medical-device-databases/code-federal-regulations-title-21-food-and-drugs
  7. Goldina TA, Suvorov NI, Remizova AV, et al. Legal aspects of non-interventional studies conduction. Medical Technologies. Assessment and Choice. 2019;4(38):40-48. (In Russ.). https://doi.org/10.31556/2219-0678.2019.38.4.040-048
  8. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration Staff. U.S. Food and Drug Administration. 2017. Accessed July 27, 2020. https://www.fda.gov/media/99447/download
  9. U.S. Food and Drug Administration. Framework for FDA’s Real-World Evidence Program. December 2018. Accessed July 27, 2020. https://www.fda.gov/media/120060/download
  10. Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drugs and Biologics: Guidance for Industry (Draft). U.S. Food and Drug Administration. May 2019. Accessed July 27, 2020. https://www.fda.gov/media/124795/download
  11. Kodeks nadlezhashchej praktiki Assotsiatsii mezhdunarodnykh farmatsevticheskikh proizvoditelej (AIPM) ot 05.12.2018 g. Accessed September 20, 2020. (In Russ.). https://www.aipm.org/netcat_files/userfiles/AIPM_Code_of_Practice_2018.pdf
  12. ICH guideline Q9 on quality risk management. European Medicines Agency, 2015. Accessed September 20, 2020. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-3.pdf
  13. Stefanov IV. Risk based monitoring does not reduce the cost of clinical trials. Kachestvennaya klinicheskaya praktika. 2016;2:71-72. (In Russ.).
  14. Bakobaki JM, Rauchenberger M, Joffe N, et al. The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial. Clinical Trials. 2012;9(2):257-264.  https://doi.org/10.1177/1740774511427325
  15. Pogue JM, Devereaux PJ, Thorlund K, et al. Central statistical monitoring: detecting fraud in clinical trials. Clinical Trials. 2013; 10(2):225-235.  https://doi.org/10.1177/1740774512469312
  16. Trotta L, Kabeya Y, Buyse M, et al. Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring. Clinical Trials. 2019;16(5):512-522.  https://doi.org/10.1177/1740774519862564
  17. Diaz-Montana C, Cragg WJ, Choudhury R, et al. Implementing monitoring triggers and matching of triggered and control sites in the TEMPER study: a description and evaluation of a triggered monitoring management system. Trials. 2019;20(1):227.  https://doi.org/10.1186/s13063-019-3301-z
  18. Love SB, Yorke-Edwards V, Lensen S., et al. Monitoring in practice — How are UK academic clinical trials monitored? A survey. Trials. 2020;21(1):59.  https://doi.org/10.1186/s13063-019-3976-1

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.